High-Tech location Germany: market chances for innovative drug candidates

02. December 2009, Museum im Kulturspeicher, Würzburg

Bildquelle: Altana Pharma, Boehringer Ingelheim

Innovative drugs offer opportunities for improved therapies and enable novel approaches for the treatment of diseases so far difficult to treat. However, the development costs of new compounds have steadily been increasing within the last years. On the other hand, the budgets of the health systems are limited. This significantly limits the market entry of innovative drugs: the market success does not only depend on the approval, but also reimbursement issues.

Experts from academia, health departments as well as pharma- and biotech industry present the current situation and discuss future impacts on the high-tech location Germany.